REPeAL Implementation Study

  • Research type

    Research Study

  • Full title

    Removal of Erroneous Penicillin Allergy Labels: implementation study(REPeAL IS)

  • IRAS ID

    335337

  • Contact name

    Neil Powell

  • Contact email

    neil.powell2@nhs.net

  • Sponsor organisation

    Royal Cornwall Hospital Trust

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Fifteen percent of hospitalised patients have a self-reported penicillin allergy (penA) record which means these patients are not prescribed first line penicillin antibiotics, instead receiving second or third line antibiotics which are associated with poorer patient outcomes (e.g. treatment failure and increased mortality) and poorer healthcare
    outcomes (e.g. increased length of hospital stay and increased treatment costs). These poorer outcomes are unnecessary because more than 90% of patients with self-reported penicillin allergy records are not allergic to penicillin and can therefore to be prescribed first line penicillin. The literature supports the safety of hospital doctors and pharmacists removing penicillin allergy records and prescribing penicillin to patients with low-risk penicillin
    allergy records.

    National and international guidelines on penA de-labelling will be used, along with the published studies on penicillin allergy de-labelling, to develop hospital-wide guidelines and a toolkit (which includes education for healthcare workers, information leaflets for patients on the risks of having a penicillin allergy label and the risks and benefits of testing, GP letter proformas to facilitate communication between secondary care and primary care, and a risk assessment tool) which aims to facilitate penicillin allergy risk assessment and de-label of adult inpatients as a standard of care and delivered by ward doctors, ward pharmacists and ward nurses.

    The penicillin allergy de-labelling patient pathway will be implemented using quality improvement methods and championed by the antimicrobial stewardship team. The study will test the implementation strategy as well as patient and healthcare worker acceptance of the patient pathway and the impact of de-labelling on antibiotic prescribing and patient outcomes. The data will be used to further optimise implementation of the patient pathway.

  • REC name

    North East - Newcastle & North Tyneside 2 Research Ethics Committee

  • REC reference

    23/NE/0231

  • Date of REC Opinion

    15 Jan 2024

  • REC opinion

    Further Information Favourable Opinion